Samsung Bioepis Gets Second US Denosumab Biosimilar As Competitors Line Up
Korean Developer Also Receives Formal EU Approval For Prolia/Xgeva Rival
Samsung Bioepis is only the second firm to receive a US FDA endorsement for its denosumab biosimilars, with the nod coming at the same time as formal European Commission approval. But plenty more firms are waiting in line with their own rivals to Prolia and Xgeva.
